On March 8, 2018, the Company acquired SafeOp, a privately-held provider of neuromonitoring technology designed to enable effective intra-operative nerve health assessment. At the time of acquisition SafeOp had FDA 510(k) approval for a somatosensory evoked potential (“SSEP”) monitoring technology. The Company has developed a product that will allow for both free run and triggered specific recording of muscle activity, also known as Electromyography (“EMG”). The Company received FDA clearance for SafeOp’s EMG technology in February 2019 to complement the SSEP solution, and anticipates commercialization of the combined technology solution in mid-2019. In addition to expanding the Company’s market presence in lateral spine surgery, the Company believes that the SafeOp solution will allow it to integrate neuromonitoring into its broader product portfolio and accelerate the transition to procedural integration of the entire portfolio.

The Merger was accounted for using the acquisition method of accounting. The following unaudited pro forma results of operations assume that the Company acquired SafeOp on January 1, 2018 and 2017, respectively (in thousands).

	Year Ended December 31,
	2018			2017
Revenue	$	91,694		$	101,981
Loss from continuing operations		(29,493	)		(8,776	)
Net loss	$	(28,975	)	$	(6,530	)
Net loss per share, basic and diluted	$	(0.69	)	$	(0.35	)

The unaudited pro forma information presented above is not necessarily indicative of either the results of operations that would have occurred had the acquisition of SafeOp been effective on January 1, 2018 or 2017, respectively, or of the Company’s future results of operations.

The results of operations for SafeOp have been included in the Company’s financial results since the acquisition date. For the year ended December 31, 2018, the Company’s total net revenues were not materially impacted from the Merger and net loss increased by $2.8 million due to SafeOp’s operating expenses.

Under the term of the definitive merger agreement, the Company agreed to pay $15.1 million in cash and agreed to issue 3,265,132 shares of common stock. The Company paid the full $15.1 million in cash consideration during the year ended December 31, 2018. On March 8, 2018, the Company issued 2,975,209 shares of common stock valued at $9.8 million, based on the closing share price of $3.30, and issued an additional 115,621 shares of common stock during the second quarter of 2018 and the remaining 174,302 shares of common stock during the third quarter of 2018.

The Company also issued $3 million in convertible notes that were convertible into a total of 987,578 shares, which included total interest incurred, of common stock and issued warrants to purchase 2.2 million shares of common stock at an exercise price of $3.50 per share. The convertible notes matured on March 9, 2019 and were settled in cash. Shares of common stock are issuable upon achievement of post-closing milestones as described further below.

Cash paid	$	15,103
Common stock issued		10,879
Note		3,000
Warrants		1,650
Contingent consideration issued or issuable		3,200
Total	$	33,832

The Company has measured the identifiable assets and liabilities assumed at their acquisition date fair values separately from goodwill. The intangible assets acquired includes the EPAD tradename, in-process research and development (“IPR&D”) for the EMG technology, and the developed technology for SSEP. The fair value of the EPAD tradename was determined to be $60,000 with an estimated useful life of one year. The IPR&D for the EMG technology is considered to have an indefinite life until the development is completed (i.e. once FDA clearance is obtained), at which point the Company will determine the intangible asset’s estimate useful life. The developed SSEP technology has an estimated fair value of $13.1 million with an estimated useful life of 20 years. The Company has not presented any measurement period adjustments to the purchase price or the allocation detailed below for the year ended December 31, 2018 due to their immaterial nature.

The allocation of the purchase price to the assets acquired and liabilities assumed based on their fair values, is as follows (in thousands):

Assets acquired:
Accounts receivable	$	40
Inventory		192
Prepaid expenses and other current assets		89
Total current assets	$	321
Property and equipment, net		20
Other long-term assets		5
IPR&D		8,400
EPAD Tradename		60
Developed Technology		13,100
Total assets	$	21,906
Liabilities assumed:
Accounts payable	$	55
Accrued expenses		148
Deferred tax liability		1,768
Total liabilities	$	1,971
Goodwill		13,897
Total consideration transferred	$	33,832

The purchase price exceeded the fair value of the net tangible and identifiable intangible assets acquired from SafeOp. As a result, the Company recorded goodwill in connection with the Merger. Specifically, the goodwill recorded as part of the Merger includes the assembled workforce and synergies associated with the combined entity. The goodwill is not expected to be deductible for tax purposes.

As a result of the Merger, for the year ended December 31, 2018, the Company incurred $1.6 million in total transaction costs which, in accordance with authoritative accounting guidance, were expensed as incurred.

The Company agreed to issue additional shares of common stock for up to $4.3 million upon achievement of post-closing milestones (the “Contingent Consideration”). The first milestone included payment of up to $1.4 million due 10 days after submission of an application for Regulatory Approval (as that term is defined in the Merger Agreement) for an indication for regulatory clearance for use of a product that includes specifically recording of muscle activity (EMG). During the third quarter of 2018, the first milestone was achieved and the Company issued 443,421 shares of common stock as payment. The second milestone includes a payment of up to $2.9 million in common stock due 10 days after the receipt of Regulatory Approval from any Regulatory Authority (as those terms are defined in the Merger Agreement) for an indication for use of a product that includes specifically EMG. During the first quarter of 2019, the second milestone was achieved and the Company issued 886,843 shares of common stock as payment. The Contingent Consideration is recorded as a liability and measured at fair value using a probability-weighted income approach, utilizing significant unobservable inputs including the probability of achieving each of the potential milestones and an estimated discount rate related to the risks of the expected cash flows attributable to the milestones. The material factors that may impact the fair value of the Contingent Consideration, and therefore, this liability, are the probabilities of achieving the related milestones and the discount rate. Significant increases or decreases in any of the probabilities of success would result in a significantly higher or lower fair value, respectively. The fair value of the Contingent Consideration, and the associated liability relating to the Contingent Consideration at each reporting date, will be re-assessed with the changes in fair value reflected in earnings. For the year ended December 31, 2018, the fair value for the Contingent Consideration increased by $0.8 million due to the proximity of the achievement of the milestones. The amount was recorded within research and development expense on the consolidated statement of operations, with a corresponding increase in the liability on the Company’s consolidated balance sheet.